Gynecological cancers are first, but if you check page 14 of the presentation, they mention, "Prolanta™ Breast Cancer: To be pursued with a pharmaceutical partner or post-approval of ovarian indication"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.